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CASE STUDY
Dengue death with evidence 
of hemophagocytic syndrome and dengue virus 
infection in the bone marrow
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Abstract 
Introduction: HPS is a potentially life‑threatening histiocytic disorder that has been described in various viral infec‑
tions including dengue.  Its involvement in severe and fatal dengue is probably more common but is presently under 
recognized.
Case description: A 38‑year‑old female was admitted after 5 days of fever. She was deeply jaundiced, leukopenic 
and thrombocytopenic.  Marked elevation of transaminases, hyperbilirubinemia and hypoalbuminemia were 
observed.  She had deranged INR values and prolonged aPTT accompanied with hypofibrinogenemia.  She also had 
splenomegaly.  She was positive for dengue IgM.  Five days later she became polyuric and CT brain image showed 
gross generalized cerebral edema.  Her conditions deteriorated by day 9, became confused with GCS of 9/15.  Her 
BMAT showed minimal histiocytes.  Her serum ferritin level peaked at 13,670.00 µg/mL and her sCD163 and sCD25 
values were markedly elevated at 4750.00 ng/mL and 4191.00 pg/mL, respectively.  She succumbed to the disease on 
day 10 and examination of her tissues showed the presence of dengue virus genome in the bone marrow.
Discussion and evaluation: It is described here, a case of fatal dengue with clinical features of HPS.  Though BMAT 
results did not show the presence of macrophage hemophagocytosis, other laboratory features were consistent 
with HPS especially marked elevation of ferritin, sCD163 and sCD25.  Detection of dengue virus in the patient’s bone 
marrow, fifteen days after the onset of fever was also consistent with the suggestion that the HPS is associated with 
dengue virus infection.
Conclusions: The findings highlight HPS as a possible complication leading to severe dengue and revealed persis‑
tent dengue virus infection of the bone marrow.  Detection of HPS markers; ferritin, sCD163 and sCD25, therefore, 
should be considered for early recognition of HPS‑associated dengue.
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Background
Dengue is recognized as one of the most important vec-
tor-borne human diseases (World Health Organization 
and the Special Programme for Research and Training in 
Tropical Diseases (TDR) 2009). The disease is endemic 
in many tropical and subtropical regions of the world 
(World Health Organization and the Special Programme 
for Research and Training in Tropical Diseases (TDR) 
2009; Brady et al. 2012). Dengue usually presents as mild 
dengue fever and most patients will recover without com-
plications. Less than 2  % of the dengue patients would 
present with the severe forms of the disease, dengue hem-
orrhagic fever (DHF) and dengue shock syndrome (DSS) 
which are characterized by severe intravascular leakages 
that could lead to hypovolemic shock and multi-organ 
failures (Avirutnam et al. 2006; Wills et al. 2004; Martina 
et al. 2009). Dengue deaths usually occur within this group 
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of dengue patients (Sam et al. 2013; Campos et al. 2015). 
While dengue is still a pediatric health concern, the infec-
tion has become more of a young adult disease in many 
endemic regions (Alexander et  al. 2011). A number of 
clinical presentations of dengue, which are typical to adult 
infections, have been documented and this has become 
the impetus for World Health Organization (WHO) to 
revise its original classification of dengue to take into 
account of other ‘atypical’ manifestations of dengue (Rowe 
et  al. 2014; Nimmagadda et  al. 2014; Hadinegoro 2012). 
Under the recent WHO classification, most of the den-
gue patients fall under the group of dengue with warning 
signs (Alexander et  al. 2011) which include abdominal 
pain or tenderness, persistent vomiting, mucosal bleed-
ing, hepatomegaly, lethargy or restlessness, thrombocyto-
penia and increased hematocrit profile. Severe dengue is 
often reported with co-morbidities such as diabetes mel-
litus, obesity, hypertension and asthma (Thein et al. 2013; 
Zakaria et al. 2014; Saqib et al. 2014). In addition to these, 
other atypical manifestations including encephalitis, rhab-
domyolysis, acute motor quadriparesis, and hemophago-
cytic syndrome (HPS) have also been described for severe 
dengue (Araujo et al. 2012; Mok et al. 2013; Gutch et al. 
2012; Ramanathan and Duraisamy 1991; Rueda et  al. 
2002; Lu et  al. 2005; Nakamura et  al. 2009; Soler et  al. 
2010; Tan et al. 2012; Sharp et al. 2014; Riberio et al. 2014; 
De Koninck et al. 2014; Mitra and Bhattacharya 2014; Pal 
et al. 2014; Phuakpet et al. 2015).
HPS is characterized by uncontrolled activation of nor-
mal T lymphocytes and macrophages, leading to over-
whelming production of pro-inflammatory cytokines 
which can cause hyperinflammation (Ravelli et al. 2012). 
HPS-associated dengue disease was reported as early as 
1966 (Janka 2012), and to date at least 44 case reports of 
HPS in dengue have been reported in the literature. HPS 
has been described especially in severe dengue (Ram-
anathan and Duraisamy 1991; Rueda et al. 2002; Lu et al. 
2005; Nakamura et al. 2009; Soler et al. 2010; Tan et al. 
2012; Sharp et al. 2014; Riberio et al. 2014; De Koninck 
et al. 2014; Mitra and Bhattacharya 2014; Pal et al. 2014; 
Phuakpet et  al. 2015) and reports of HPS in confirmed 
dengue cases, presented clinical and diagnostic features 
similar to those of HPS which include hyperferritine-
mia and hemophagocytosis activity in the bone marrow. 
However, most of these earlier reports did not include 
the evidence of other distinct features of HPS such as 
elevated levels of soluble CD163 (sCD163) and soluble 
CD25 (sCD25) (Ravelli et al. 2012; Bleesing et al. 2007). 
Even though the number of reported cases of HPS in 
dengue in the literature is low, it is possible that the inci-
dence could be much higher due to its under-recognition. 
Here we report a case of fatal dengue with typical HPS 
presentations including the detection of dengue virus in 
the bone marrow and the use of serum biomarkers of 
HPS in the detection of severe dengue.
Case report
A 38-year-old female was admitted to the University of 
Malaya Medical Centre (UMMC), Kuala Lumpur after 
5 days of fever with right hypochondriac region abdomi-
nal pain, persistent vomiting, myalgia, headache and an 
episode of epistaxis. She also complained of passing tea-
colored urine for 3  days duration and 2  days history of 
dry cough with right-sided pleuritic chest pain. There 
was no recent travel history and other household mem-
bers were well. She denied any substance abuse, had 
blood transfusion or consumed any herbal or traditional 
medicines. There was no past medical and family history 
of connective tissue diseases (CTD) or hepatitis. She was 
not on any immunosuppressant or other regular medica-
tions and CTD screening was not performed. On admis-
sion, she was alert and deeply jaundiced. She was found 
to be febrile (38.6 °C), normotensive (110/70 mmHg) but 
tachycardic (100  bpm). There was no flapping tremor 
to suggest hepatic encephalopathy. The abdomen was 
generally soft with tender hepatomegaly. Cardiovas-
cular, respiratory and neurological examinations were 
unremarkable.
Her full blood count showed leukopenia and throm-
bocytopenia (Fig.  1a). Her liver function tests showed 
marked elevation of transaminases as well as hyperbili-
rubinemia and hypoalbuminemia (Fig. 1b). Her coagula-
tion profile showed deranged international normalized 
ratio (INR) values and prolonged activated partial throm-
boplastin time (aPTT) accompanied with hypofibrin-
ogenemia (Fig.  1c). Abdominal ultrasound revealed 
non-specific increased in peri-portal echogenicity with 
‘starry sky’ appearance, consistent with acute hepatitis. 
There was neither biliary obstruction nor ascites noted. 
She was hydrated with maintenance normal saline drip 
of 1 cc/kg/h. She was empirically started on intravenous 
infusion (IVI) Ceftriaxone and given intravenous vitamin 
K 10 mg once daily. She was tested negative for malaria, 
hepatitis B and C. Paracetamol and salicylate levels were 
undetectable. Blood cultures were negative for any bacte-
rial or fungal growth.
At day 2 of admission (day 7 of illness), she remained 
alert but tachycardic. IgM serology test for dengue was 
positive. Clinical examination revealed minimal right-
sided pleural effusion. In view of the worsening coagu-
lation profile, she was transfused with 4 units of fresh 
frozen plasma and four units of cryoprecipitate. There 
was no bleeding tendency. Throughout her stay, her urine 
output and blood pressure were satisfactory. Thrombotic 
thrombocytopenic purpura (TTP) was ruled out as the 
peripheral blood film (PBF) was not suggestive and her 
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renal function was normal. However, she was found to 
have splenomegaly.
By day 4 of hospitalization (day 9 of illness), she became 
confused and drowsy. Her Glasgow Coma Scale (GCS) 
was 9/15 (E3V1M5). Kernig’s sign was negative. Pupils 
were 5  mm equal and reactive bilaterally. She remained 
afebrile. Her blood pressure (BP) was 105/75 mmHg with 
heart rate 144 beats per minute. There was no focal neu-
rological deficit with bilateral down-going plantar. Plain 
computed tomography (CT) of the brain showed no evi-
dence of intracranial bleed or focal lesion. In view of the 
profound thrombocytopenia as well as marked coagu-
lopathy, a lumbar puncture was not performed. She was 
electively intubated due to deteriorating conscious level 
and for airway protection. Broad-spectrum antibiotics 
were introduced which included IVI meropenem and 
IVI azithromycin. Blood products were transfused in an 
attempt to correct her coagulopathy. The gastroenterol-
ogy team was consulted for her worsening liver function 
and she was started on IVI N-acetyl cysteine. Her serum 
ferritin on day 6 of illness was 6307.33 µg/L, suggesting 
possible macrophage activation syndrome (MAS) or HPS 
secondary to dengue virus infection. Intravenous dexa-
methasone of 8.00 mg TID was started. A bone marrow 
trephine and aspiration (BMAT) was performed to con-
firm this diagnosis.
On day 5 of hospitalization (day 10 of illness), she 
became polyuric. A repeated CT brain imaging showed 
Fig. 1 Laboratory diagnostic profiles of a dengue patient with HPS presentation. a Full blood count analysis b Liver function tests c Coagulation 
profile d Body temperature and level of ferritin. INR International normalised ratio, aPTT activated partial thromboplastin time
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gross generalized cerebral oedema. Further investigations 
confirmed a diagnosis of cranial diabetes insipidus (DI). 
The hematologist reviewed the BMAT, which showed 
minimal histiocytes that was less likely to be diagnostic 
for HLH. However, a diagnosis of dengue virus infection 
associated with subsequent HPS was established due to 
elevated serum level of HPS biomarkers and other clini-
cal diagnostic criteria (Pal et  al. 2014). Serum HPS bio-
markers including ferritin, haptoglobin, soluble CD163 
(sCD163) and soluble CD25 (sCD25) were measured. 
Her ferritin level peaked on day 2 of hospitalization (day 
7 of illness) at 13,670.00  µg/mL and decreased there-
after (Fig.  1d). Soluble haptoglobin, CD163 and CD25 
determined using commercially available enzyme-linked 
immunosorbent assay kits (Genway, San Diego; R&D Sys-
tem, Minneapolis) showed a very low level of haptoglobin 
(0.05 g/L) compared to healthy donor group with mean 
value of 228.49  g/L (data not shown). Highly elevated 
levels of sCD163 and sCD25 with values of 4750.00 ng/
mL and 4191.00  pg/mL, respectively, in comparison to 
mean values of 261.65  ng/mL (sCD163) and 483.69  pg/
mL (sCD25) of a group of healthy donors (n = 39) (data 
not shown) were observed. Despite our best effort and 
aggressive medical intervention, the patient succumbed 
to her ordeal by day 10 of hospitalization.
Tissue specimens of bone marrow, peritoneal fluid and 
throat swab obtained during post-mortem were used for 
nucleic acid amplification assays using general Flavivirus 
amplification primers (Teoh et  al. 2013). Only the bone 
marrow tissue sample was positive for partial sequences 
of non-structural proteins NS1, NS2A, NS4b and NS5. 
Bidirectional DNA sequencing results confirmed the 
presence of nucleotide sequences matching that of 
DENV-2 with 99 % sequence similarity (data not shown).
Dengue viruses can cause a spectrum of disease rang-
ing from mild flu-like fever to hemorrhagic fever with 
severe intravascular leakages and hypovolemic shock 
(Martina et  al. 2009). The 2009 revised World Health 
Organization (WHO) dengue classification character-
ized severe dengue as dengue with severe plasma leakage, 
severe organ impairment or severe hemorrhage (World 
Health Organization and the Special Programme for 
Research and Training in Tropical Diseases (TDR) 2009). 
Although a clear molecular mechanism leading to severe 
dengue is still not well understood, it is thought that mac-
rophage activation syndrome may have a role in some 
cases of severe dengue (Ramanathan and Duraisamy 
1991; Rueda et  al. 2002; Lu et  al. 2005; Nakamura et  al. 
2009; Soler et al. 2010; Tan et al. 2012; Sharp et al. 2014; 
Riberio et  al. 2014; De Koninck et  al. 2014; Mitra and 
Bhattacharya 2014; Pal et al. 2014; Phuakpet et al. 2015). 
The increasing reports of hemophagocytosis associated 
with dengue infection in both endemic and non-endemic 
areas have raised concern of the potential threat of this 
emerging syndrome in causing severe and fatal compli-
cations of dengue (Ramanathan and Duraisamy 1991; 
Rueda et  al. 2002; Lu et  al. 2005; Nakamura et  al. 2009; 
Soler et al. 2010; Tan et al. 2012; Sharp et al. 2014; Riberio 
et al. 2014; De Koninck et al. 2014; Mitra and Bhattacha-
rya 2014; Pal et al. 2014; Phuakpet et al. 2015).
Clinically, according to the 2009 revised World Health 
Organization (WHO) dengue classification, the patient 
in our study met the criteria of severe dengue with pres-
entations of severe hemorrhage and liver failure. Her 
low haptoglobin level provided evidence of bleeding 
and liver impairment, resulting in poor coagulation pro-
file and markedly elevated liver enzymes. Furthermore, 
our initial suspicion that the patient was having HPS 
as a possible complication was supported by laboratory 
findings of elevated levels of serum ferritin, sCD163 
and sCD25 typical of HPS (Ravelli et  al. 2012; Bleesing 
et al. 2007). Although observation of hemophagocytosis 
is the gold standard for identifying macrophage activa-
tion syndrome, specific biomarkers are needed for its 
early detection. In this case, serum ferritin, sCD163 
and sCD25 levels were charted during the course of her 
hospitalization. Elevated transaminases levels were also 
observed; and this was similar to an earlier observation 
which supports the possibility of HPS contributing to 
hepatic dysfunction (Lu et  al. 2005). We also detected 
dengue viral RNA in the bone marrow tissue samples, 
providing direct evidence of the presence of dengue 
virus in the tissue. This was consistent with previous 
reports highlighting the involvement of bone marrow in 
dengue virus infection (Nelson et al. 1966; Nisalak et al. 
1970). It is also worth noting that the dengue virus per-
sisted in the bone marrow even at 15 days post onset of 
fever and long after viremia was over. Currently, it is not 
known how long dengue virus would persist in the mar-
row following an infection.
Conclusions
We present here a fatal case of dengue with clinical and 
laboratory findings suggesting the involvement of HPS 
and evidence supporting dengue virus infection of the 
bone marrow, detectable even on day 15 after the onset 
of fever. These findings emphasized HPS as a serious 
complication of dengue and that dengue virus persisted 
in the bone marrow long after viremia is over. A reli-
able treatment strategy for combating dengue-associated 
HPS, however, is yet to be established. Early detection of 
HPS biomarkers and treatment with methylprednisolone 
or dexamethasone at appropriate dosage may prevent 
further complications and death (Mitra and Bhattacharya 
2014; Wan Jamaluddin et al. 2015) but this requires fur-
ther investigation.
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Consent
A written informed consent was obtained. The study 
received approval from the University of Malaya Medi-
cal Centre (UMMC) Medical Ethics Committee (Eth-
ics Number—908.9). The study conformed to the 
Declaration of Helsinki and Malaysian Good Clinical 
Practice (GCP) guidelines.
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